The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Active Ingredient: DEFERASIROX
Proprietary Name: DEFERASIROX
Dosage Form; Route of Administration: GRANULE; ORAL
Strength: 90MG
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A215026
Product Number: 001
Approval Date: Feb 23, 2022
Applicant Holder Full Name: CIPLA LTD
Marketing Status:
Prescription
Patent and Exclusivity Information
Active Ingredient: DEFERASIROX
Proprietary Name: DEFERASIROX
Dosage Form; Route of Administration: GRANULE; ORAL
Strength: 180MG
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A215026
Product Number: 002
Approval Date: Feb 23, 2022
Applicant Holder Full Name: CIPLA LTD
Marketing Status:
Prescription
Patent and Exclusivity Information
Active Ingredient: DEFERASIROX
Proprietary Name: DEFERASIROX
Dosage Form; Route of Administration: GRANULE; ORAL
Strength: 360MG
Reference Listed Drug: No
Reference Standard: No
TE Code: AB
Application Number: A215026
Product Number: 003
Approval Date: Feb 23, 2022
Applicant Holder Full Name: CIPLA LTD
Marketing Status:
Prescription
Patent and Exclusivity Information